Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Loxo Oncology, Inc.
Scientific Title
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity